Stocks · News reference
Analyst Samantha Semenkow Maintains Bullish Rating on Spyre Therapeutics
Analyst Samantha Semenkow has reaffirmed a bullish rating on Spyre Therapeutics, maintaining a price target of $119.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading